Ankylosing Spondylitis News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Lilly chases third Taltz-Cosentyx matchup with new ankylosing spondylitis data - FiercePharma



FiercePharma
 
Lilly chases third Taltz-Cosentyx matchup with new ankylosing spondylitis data 
FiercePharma
Lilly chases third Taltz-Cosentyx matchup with new ankylosing spondylitis data. by Carly Helfand |. Feb 14, 2018 9:13am. lilly. Eli Lilly was the first to use ASAS40 as its primary endpoint in a registration trial, it said. (Eli Lilly). Share Facebook ...
Lilly's Taltz hits goals in PhIII ankylosing spondylitis trial PharmaTimes
Eli Lilly Announces Positive Results for IL-17 Inhibitor in Treating Ankylosing Spondylitis The Center for Biosimilars
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) in Ankylosing Spondylitis Drug Discovery & Development
Nasdaq  -BioPharma Dive 
all 8 news articles » 


NICE Recommends Simponi for Severe Non-Radiographical AS in England, Wales - Ankylosing Spondylitis News



Ankylosing Spondylitis News
 
NICE Recommends Simponi for Severe Non-Radiographical AS in England, Wales 
Ankylosing Spondylitis News
Treatment with Merck's Simponi (golimumab) is now recommended for patients with severe non-radiographic axial spondyloarthritis (nr-axial SpA) in England and Wales. Nr-axial SpA and ankylosing spondylitis (AS) are collectively called axial ...

 


Lilly Announces Positive Top-Line Phase 3 Results for Taltz« (ixekizumab) in Ankylosing Spondylitis (Radiographic ... - PR Newswire (press release)



Nasdaq
 
Lilly Announces Positive Top-Line Phase 3 Results for Taltz« (ixekizumab) in Ankylosing Spondylitis (Radiographic ... 
PR Newswire (press release)
INDIANAPOLIS, Feb. 13, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz« (ixekizumab) met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and efficacy of Taltz for the ...
Lilly's Taltz successful in late-stage study in ankylosing spondylitis Seeking Alpha
Eli Lilly: Taltz Phase 3 Study Meets Endpoints To Treat Ankylosing Spondylitis Nasdaq
Eli Lilly & Co. (LLY) Phase 3 Study for Taltz in Ankylosing Spondylitis Met Primary, Secondary Endpoints StreetInsider.com
The Pharma Letter  -Endpoints News 
all 5 news articles » 


Positive Results for Ixekizumab in the Treatment of Ankylosing Spondylitis - Monthly Prescribing Reference



pharmaphorum
 
Positive Results for Ixekizumab in the Treatment of Ankylosing Spondylitis 
Monthly Prescribing Reference
Eli Lilly announced positive Phase 3 data for Taltz (ixekizumab) supporting the safety and efficacy of the drug in the treatment of ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (axSpA). Taltz met the primary and major ...
Eli Lilly: Taltz Phase 3 Study Meets Endpoints To Treat Ankylosing ... Markets Insider
Lilly aims for new indication for Taltz - Pharmaphorum pharmaphorum

all 3 news articles » 


Secukinumab efficacy persists at 3 years in ankylosing spondylitis - Healio



Secukinumab efficacy persists at 3 years in ankylosing spondylitis 
Healio
Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis over a 3-year period, with no new safety signals, according to findings from an extension of the phase 3 MEASURE 1 trial, published in Clinical and Experimental ...

 


Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety - Rheumatology Advisor



Rheumatology Advisor
 
Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety 
Rheumatology Advisor
Treatment with secukinumab in patients with active ankylosing spondylitis (AS), particularly patients na´ve to antitumor necrosis factor therapy, is associated with rapid, significant, and sustained improvement in signs and symptoms of the disease over ...

 


Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis? - Rheumatology Advisor



Rheumatology Advisor
 
Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis? 
Rheumatology Advisor
Biologic disease-modifying antirheumatic drugs (bDMARDs) appeared to have no medium-term effect on spinal fracture risk related to ankylosing spondylitis, according to a longitudinal multiregistry observational cohort study published in BMJ Open.1 ...

 


Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis - Rheumatology Advisor



Rheumatology Advisor
 
Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis 
Rheumatology Advisor
The use of biologic disease-modifying antirheumatic drugs (bDMARDs) has no medium-term effect on the risk for spinal fractures among patients with ankylosing spondylitis (AS), according to the results of a recent study conducted in Sweden and published ...

 


Is Novartis' Psoriasis Drug Going to Steal Humira's Crown? - Labiotech.eu (blog)



Labiotech.eu (blog)
 
Is Novartis' Psoriasis Drug Going to Steal Humira's Crown? 
Labiotech.eu (blog)
Two clinical studies have demonstrated the capacity of Novartis' monoclonal antibody to treat both plaque and scalp psoriasis and improve patient quality of life. Not only is Novartis leading the CAR-T cell therapy field with the approval of Kymriah ...
New Cosentyx data confirms robust efficacy and QoL improvements ... The Pharma Letter
Novartis' Cosentyx shows quality of life benefits for plaque psoriasis ... Zenopa

all 6 news articles » 


Patients Who Don't Respond Initially to TNFi inhibitors Share Similarities, Study Finds - Ankylosing Spondylitis News



Ankylosing Spondylitis News
 
Patients Who Don't Respond Initially to TNFi inhibitors Share Similarities, Study Finds 
Ankylosing Spondylitis News
The study included 249 axial spondyloarthritis patients who were taking TNF inhibitors for the first time. Records in the database at the adult Spondylitis Clinic at the Toronto Western Hospital from patients seen between July 2003 and December 2016 ...